Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 33.75 USD -2.46%
Market Cap: 1.7B USD

EV/EBITDA
Enterprise Value to EBITDA

166.9
Current
-64.4
Median
5.4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
166.9
=
Enterprise Value
1.6B USD
/
EBITDA
9.5m USD
EBITDA Growth EV/EBITDA to Growth
US
Vericel Corp
NASDAQ:VCEL
Average EV/EBITDA: 37
166.9
138%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
14.4
12%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -456.7 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
21.9
2-Years Forward
EV/EBITDA
15.9
3-Years Forward
EV/EBITDA
11.7